JPMorgan Chase & Co. set a €57.90 ($67.33) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research report released on Wednesday morning, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
Several other research analysts also recently commented on the stock. Berenberg Bank set a €70.95 ($82.50) price objective on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Thursday, May 2nd. Warburg Research set a €65.00 ($75.58) price objective on shares of Fresenius SE & Co KGaA and gave the company a buy rating in a research report on Thursday, July 11th. Jefferies Financial Group set a €40.00 ($46.51) target price on shares of Hapag-Lloyd and gave the stock a buy rating in a research note on Thursday, May 2nd. HSBC set a €101.00 ($117.44) target price on shares of Grenke and gave the stock a buy rating in a research note on Thursday, April 25th. Finally, Barclays reaffirmed a hold rating and set a $14.00 target price on shares of MACOM Technology Solutions in a research note on Thursday, June 20th. Nine equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of €58.70 ($68.26).
Shares of FRE opened at €45.03 ($52.36) on Wednesday. Fresenius SE & Co KGaA has a one year low of €60.16 ($69.95) and a one year high of €80.00 ($93.02). The company’s 50 day moving average price is €46.87.
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.
Featured Story: What is the price-to-earnings growth (PEG) ratio?
Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.